---
title: "Diabetes Medications"
tags: [medications, diabetes, endocrinology]
sidebar: ccms_medications_sidebar
permalink: /medications/diabetes-medications.html
summary: Comprehensive guide to diabetes medications including oral agents, injectables, and insulin therapy
---

# Diabetes Medications

Comprehensive medication reference for diabetes management including oral agents, injectables, and insulin therapy.

## Oral Antidiabetic Agents

### Metformin
**Mechanism**: Decreases hepatic glucose production, increases insulin sensitivity

- **Starting Dose**: 500mg daily with evening meal
- **Max Dose**: 2000mg daily (1000mg BID)
- **Advantages**: First-line, weight neutral, cardiovascular benefits
- **Side Effects**: GI upset, lactic acidosis (rare)
- **Contraindications**: eGFR <30, severe heart failure, contrast studies

### Sulfonylureas
**Mechanism**: Stimulate insulin secretion from pancreatic beta cells

| Medication | Starting Dose | Max Dose | Duration |
|------------|---------------|----------|----------|
| Glipizide | 5mg daily | 20mg daily | Short-acting |
| Glimepiride | 1mg daily | 8mg daily | Long-acting |
| Glyburide | 2.5mg daily | 20mg daily | Long-acting |

**Side Effects**: Hypoglycemia, weight gain
**Monitoring**: Blood glucose, HbA1c

### DPP-4 Inhibitors
**Mechanism**: Inhibit DPP-4 enzyme, increase GLP-1 levels

| Medication | Dose | Frequency | Advantages |
|------------|------|-----------|------------|
| Sitagliptin | 100mg | Daily | Well-tolerated |
| Linagliptin | 5mg | Daily | Renal adjustment not needed |
| Saxagliptin | 5mg | Daily | Cardiovascular safety |

**Side Effects**: Nasopharyngitis, pancreatitis (rare)
**Advantages**: Weight neutral, low hypoglycemia risk

## Injectable Agents

### GLP-1 Receptor Agonists
**Mechanism**: Mimic GLP-1, increase insulin secretion, decrease glucagon

| Medication | Dose | Frequency | Advantages |
|------------|------|-----------|------------|
| Liraglutide | 0.6-1.8mg | Daily | Weight loss, CV benefits |
| Semaglutide | 0.25-1mg | Weekly | Potent, CV benefits |
| Dulaglutide | 0.75-1.5mg | Weekly | Convenient |

**Side Effects**: Nausea, vomiting, pancreatitis (rare)
**Contraindications**: Personal/family history of medullary thyroid cancer

### SGLT2 Inhibitors
**Mechanism**: Block glucose reabsorption in kidneys

| Medication | Dose | Frequency | Benefits |
|------------|------|-----------|---------|
| Empagliflozin | 10-25mg | Daily | CV, renal benefits |
| Dapagliflozin | 5-10mg | Daily | HF benefits |
| Canagliflozin | 100-300mg | Daily | CV benefits |

**Side Effects**: Genital mycotic infections, UTIs, DKA (rare)
**Monitoring**: eGFR, ketones if symptoms

## Insulin Therapy

### Basal Insulin
**Long-acting insulins for background glucose control**

| Insulin | Onset | Peak | Duration | Dosing |
|---------|-------|------|----------|--------|
| Glargine | 2-4h | None | 24h | Once daily |
| Detemir | 2-4h | 6-8h | 12-20h | Once/twice daily |
| Degludec | 1-2h | None | 42h | Once daily |

**Starting Dose**: 0.1-0.2 units/kg/day
**Titration**: Increase by 2-4 units every 3 days

### Prandial Insulin
**Rapid-acting insulins for meal coverage**

| Insulin | Onset | Peak | Duration | Timing |
|---------|-------|------|----------|--------|
| Lispro | 15min | 1-2h | 3-4h | 15min before meals |
| Aspart | 15min | 1-2h | 3-4h | 15min before meals |
| Glulisine | 15min | 1-2h | 3-4h | 15min before meals |

**Dosing**: 0.1 units/kg per meal
**Carbohydrate Ratio**: Start 1:15, adjust based on postprandial glucose

### Premixed Insulin
**Fixed combinations of rapid and intermediate-acting insulin**

| Insulin | Ratio | Dosing | Advantages |
|---------|-------|--------|------------|
| 70/30 | 70% NPH, 30% regular | BID | Convenient |
| 75/25 | 75% NPL, 25% lispro | BID | Better postprandial control |

## Combination Therapy

### Rational Combinations
- **Metformin + SGLT2i**: Synergistic, weight loss
- **Metformin + GLP-1**: Weight loss, CV benefits
- **Metformin + DPP-4i**: Well-tolerated, low hypoglycemia
- **Basal insulin + GLP-1**: Better control, less weight gain

### Treatment Algorithms
1. **First-line**: Metformin + lifestyle
2. **Second-line**: Add SGLT2i or GLP-1 (if CV/HF risk)
3. **Third-line**: Add basal insulin or sulfonylurea
4. **Fourth-line**: Intensify insulin or add prandial insulin

## Monitoring and Safety

### Glucose Monitoring
- **Frequency**: Based on treatment regimen
- **Targets**: Fasting 80-130 mg/dL, postprandial <180 mg/dL
- **HbA1c**: Every 3 months if not at target

### Safety Monitoring
- **Hypoglycemia**: Blood glucose <70 mg/dL
- **DKA**: Blood glucose >250 mg/dL, ketones positive
- **Renal Function**: eGFR monitoring for SGLT2i
- **Cardiovascular**: Monitor for HF symptoms

## Drug Interactions

### Major Interactions
- **Sulfonylureas + Alcohol**: Hypoglycemia risk
- **Metformin + Contrast**: Lactic acidosis risk
- **Warfarin + Metformin**: Increased INR
- **Beta-blockers + Insulin**: Masked hypoglycemia symptoms
